Pulmonary Hypertension

HomePatientsLung Disease Week at the ATS2011 ▶ Pulmonary Hypertension
Pulmonary Hypertension Disease

Pulmonary Hypertension

Welcome Message

Pulmonary arterial hypertension (PAH) is high blood pressure in the arteries of the lungs and can lead to heart failure and death. Before 1996, there were no effective disease-specific treatments for pulmonary arterial hypertension and the disease was highly lethal.  Today we have seven different medical therapies approved to treat the disease in the US. That’s more treatments than for all but two of the roughly 7,000 identified rare diseases. Also, we have learned much about how to best manage the disease, so patients are doing much better than they used to.

While that is good news — and PAH in many patients is now being managed successfully with improved symptoms and prolonged survivals — the disease remains incurable and survivals are still too often too short.  Another difficulty is that the disease often goes undiagnosed or is unrecognized until late in its progression, making the available treatments less effective.

The American Thoracic Society and the Pulmonary Hypertension Association welcomes you to this website and to “Pulmonary Hypertension Week at the ATS” and hope that you will take the opportunity to learn more about this disease.


Nicholas S. Hill, MD            
American Thoracic Society

Rino Aldrighetti
President and CEO
Pulmonary Hypertension Association
Member, ATS Public Advisory Roundtable

ATS PAH PARtner  — Pulmonary Hypertension Association

The mission of the Pulmonary Hypertension Association (PHA) is to find ways to prevent and cure pulmonary hypertension, and to provide hope for the pulmonary hypertension community through support, education, advocacy and awareness.

The PHA is a young organization, changing the history of an illness. From simple beginnings — four women around a kitchen table in Florida in 1990 — PHA has evolved in size and complexity.  Membership now includes over 13,000 patients and family members as well as two medical membership sections, one for physicians and researchers, the other for allied health professionals.  The synergy created from the partnership of these constituencies has resulted in a community of hope and effective change.

Disclaimer: "The ATS Lung Disease Week Web site is designed for educational purposes only. You should not rely on this information as a substitute for personal medical attention, a diagnosis from a physician, or direct medical care.  If you are concerned about your health or that of a family member, please consult your family's healthcare provider immediately. Do not wait for a response from our members, staff or partners."